Adipose derived allogenic stem cell therapy- UnicoCell Biomed

Drug Profile

Adipose derived allogenic stem cell therapy- UnicoCell Biomed

Alternative Names: ADSCs; Elixcyte

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator UnicoCell Biomed
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Osteoarthritis
  • Preclinical Liver failure; Renal failure

Most Recent Events

  • 21 Oct 2016 Preclinical trials in Liver failure in Taiwan before October 2016 (Parenteral) (Unicocell Biomed pipeline, October 2016)
  • 13 Oct 2016 UnicoCell Biomed plans a phase I/II trial for Renal failure (In adults, In the elderly) in Taiwan (NCT02933827)
  • 01 Oct 2016 Preclinical trials in Renal failure in Taiwan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top